Publications by authors named "H A Bern"

Background: Shorter regimens for drug-resistant tuberculosis (DR-TB) have non-inferior efficacy compared with longer regimens, but QT prolongation is a concern. T-wave morphology abnormalities may be a predictor of QT prolongation.

Research Design And Methods: STREAM Stage 1 was a randomized controlled trial in rifampicin-resistant TB, comparing short and long regimens.

View Article and Find Full Text PDF

Background: Stage 1 of the STREAM trial demonstrated that the 9 month (Short) regimen developed in Bangladesh was non-inferior to the 20 month (Long) 2011 World Health Organization recommended regimen. We assess the association between HIV infection and radiographic manifestations of tuberculosis and factors associated with time to culture conversion in Stage 1 of the STREAM trial.

Methods: Reading of chest radiographs was undertaken independently by two clinicians, and films with discordant reading were read by a third reader.

View Article and Find Full Text PDF

The aim of this study is to identify the factors associated with peripheral neuropathy and to explore neurofilament light chain (NfL) as a biomarker for peripheral neuropathy (PN) in effectively virologically suppressed adults living with HIV. All protease inhibitor monotherapy versus ongoing triple therapy in the long-term management of HIV infection (PIVOT) trial participants with data on PN at baseline were included in the study. NfL plasma levels (pNfL) were measured in a sub-set of participants.

View Article and Find Full Text PDF

Introduction: The successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination. However, poor adherence compromises its therapeutic effectiveness. Novel rifapentine-based regimens and treatment support based on behavioural science theory may improve treatment adherence and completion.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers tested a new COVID-19 vaccine called LNP-nCoVsaRNA on healthy adults aged 18-75 to see if it was safe and could create an immune response.
  • The study involved giving participants two doses of the vaccine (one smaller and one larger) about 14 weeks apart, and they monitored any side effects and looked for antibodies in their blood.
  • Results showed that most participants developed antibodies against the virus, and the vaccine was generally well-tolerated, meaning it didn't cause serious problems.
View Article and Find Full Text PDF